ABSTRACT-The correlation between the binding of NZ-105, a newly synthesized 1,4-dihydropyridine (DHP) derivative, on DHP receptors and its inhibitory activity on transmembrane 45Ca2+ uptake was investigated. 3H-NZ-105 bound rabbit aortic microsomes more slowly than did 3H-nitrendipine (3H-NTD): the association and dis sociation rate constants of 3H-NZ-105 were about 70 times and 10 times less than those of 3H-NTD, respectively. The dissociation constant (Kd) of 3H-NZ-105 (4.48 nM) was about 6 times larger than that of 3H-NTD (0.79 nM), and the maximum number of binding sites (B,,,a,) for 3H-NZ-105 (112.5 fmoles/mg protein) was about the same as that for 3H-NTD (106.2 fmoles/mg protein). Unlabelled NZ-105 and nicardipine fully, and in a concentration-dependent manner, displaced 3H-NZ-105 spe cific binding. Pre-incubation with NZ-105 also concentration-dependently (more than 0.1 ,uM) inhibited the transmembrane 45Ca2+ uptake increment induced by a high-K+ (50 mM) solution. The inhibitory efficacy of NZ-105 became larger as the incubation period with this compound increased (from 1 hr incubation to 3 hr incubation), and recovery was difficult even after washout for 3 hr. Based on these results, we conclude that NZ-105 causes blockade of voltage-dependent calcium channels (VDCs) by bind ing to DHP receptors. Moreover, the very slow onset and recovery from NZ-105-in duced vasodilation may be attributable to the slow and long-lasting inhibition of trans membrane calcium uptake, which accompanies its very slow binding to and dissocia tion from DHP receptors.
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The slow inward calcium current that is car ried through voltage-dependent calcium chan nels (VDCs) plays an important role in the regulation of vascular smooth muscle contrac tility. Furthermore, it is well-known that 1,4 DHP derivatives have a regulatory effect on calcium influx through this type of channel on the cell membrane.
NZ-105, (±)-2-[benzyl(phenyl)amino] ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo 1,3,2-dioxaphosphorinan-2-yl)-4-(3-nitrophenyl) 3-pyridinecarboxylate hydrochloride ethanol, belongs to the family of 1,4-DHP derivatives, which we are developing as new antihyperten sive agents. We have previously demonstrated that NZ-105 had a characteristic antihyperten sive action which was much slower in onset and longer-lasting than that of nicardipine in several hypertensive animal models (1, 2) . Moreover, we have already reported that NZ 105 appears to have a vasodilatory effect attri butable to its calcium antagonistic effects in high-K+ precontracted rabbit arteries (3) . Both onset of and recovery from these effects of NZ-105 were markedly slow. NZ-105 specif ically bound to the binding sites (DHP recep tors) to which other 1,4-DHP derivatives spe cifically bind (3) . To explain the mechanism underlying these comparatively slower effects of NZ-105 in our previous in vitro studies, we have indirectly investigated the binding prop erties of NZ-105 for DHP receptors on rabbit aortic microsomes by a radioreceptor study us ing 3H-nitrendipine (3H-NTD) as a tracer of 1,4-DHPs (3). Our data suggested that the association rate of NZ-105 for DHP receptors was slower than those of nifedipine and nicar dipine.
In the present studies, to clarify the mechanisms underlying the very slow effects of NZ-105 in in vitro studies, we used radiolabelled NZ-105 (3H-NZ-105) and direct ly investigated the receptor binding properties of 3H-NZ-105 for DHP receptors on rabbit aortic microsomes. Furthermore, we con firmed the time-course of the changes in the inhibitory effect of NZ-105 and other calcium antagonists against the high-K+-induced trans membrane 45Ca2+ uptake increment in iso lated rabbit aorta. A part of this study was presented at the 63rd General Meeting of the Japanese Pharmacological Society (Tokyo, Japan, 1990) (4) and at the 11th International Congress of Pharmacology (Amsterdam, Netherlands, 1990) (5).
MATERIALS AND METHODS
Male Japanese white rabbits weighing 1.8 3.0 kg were used. These animals were purch ased from Tokyo Animal Laboratory, Inc. (Tokyo, Japan). All rabbits were sacrificed by venesection under deep anesthesia induced by intravenous injection of an excess dose of sodium pentobarbital.
Membrane preparations of rabbit aorta
Crude microsomal preparations of rabbit aortae were prepared in accordance with a modification of an earlier described method (6) as follows: Both thoracic and abdominal aortae were dissected free and fastidiously cleaned of adherent fat and connective tissue while maintained in oxygenated Krebs-Hen seleit solution of the following composition: 118.4 mM NaCI, 4.7 mM KC1, 1.2 mM MgS04, 2.5 mM CaC12, 1.2 mM KH2PO4, 25.0 mM NaHCO3 and 11.7 mM glucose, at 37°C. The pooled thoracic and abdominal aortae were finely minced with scissors and homoge nized in 20 volumes of ice-cold 50 mM Tris HCl buffer (pH 7.4) by means of ten 5-sec bursts on a Polytron~R (Kinematica, Switzer land) at a setting of 7. The homogenate was pestled and filtered through four layers of gauze. The homogenate was then centrifuged at 100,000 X g for 60 min at 4°C, and the pel let was resuspended in ice-cold Tris-HCl buf fer by means of a 2-sec burst on a Polytron R This washed suspension was then re-centri fuged at 100,000 X g for 60 min at 4°C, and the final pellet was resuspended, as above, us ing a Tris-HC1 buffer, to a concentration of about 5 mg protein/ml buffer; These crude microsomal preparations were stored at -80°C until use . The concentration of protein was determined by the method of Lowry et al. (7) using bovine serum albumin as a standard.
Receptor binding studies
The crude microsomal preparations (1 mg protein/ml) were pre-incubated for 3 hr at 25°C in the presence or absence of 10 ,u M un labelled NZ-105 or 10 ,u M nicardipine in ad vance of the incubation with 3H-NZ-105 or 3H -NTD , respectively. After the incubation, 3H -NZ-105 or 3H-NTD was added in the in cubation mixture and continuously incubated for various times at 25°C in a total volume of 300 pl. The incubation mixture was diluted with 5 ml of ice-cold Tris-HC1 buffer, vacuum filtered through a glass fiber filter (GF/C, Whatman, Maidstone, England) and washed with 20 ml of ice-cold buffer at a flow rate of 1 ml/sec. The filters were then dried and placed in scintillation vials with 5 ml scintilla tor (Econo-fluor R , New England Nuclear, England) for at least 3 hr, and the radioactiv ity was counted with a liquid scintillation counter (Tri-Carb R 340CD, Packard, Switzer land) at an efficacy of 45%. Specific binding of each 3H-compound was defined as total binding minus blanks determined in the pres ence of 10 ,uM of either unlabelled DHP de rivative.
The time course of the association of 3H NZ-105 or 3H-NTD was determined by adding 10 nM 3H-NZ-105 or 1 nM 3H-NTD to assay mixtures which had been pre-incubated with the crude microsomal preparations and an ex cess concentration (10,uM) of an unlabeled 1,4-DHP derivative (NZ-105 or nicardipine, respectively) for 3 hr at 25°C. The time courses for dissociation of each 3H-compound were determined by adding 10,uM nicardipine after incubating with 10 nM 3H-NZ-105 for 2 hr or 1 nM 3H-NTD for 30 min. The associa tion rate constant (k,) and dissociation rate constant (k-,) were determined by fitting the data to kinetic equations as described in detail elsewhere (8) .
In the saturation assay for determination of receptor density and the affinity of each 3H compound, the crude microsomal preparations were incubated in five increasing concentra tions of 3H-NZ-105 or 3H-NTD for 3 hr. Each 3H -compound dissociation constant (Kd) and the maximum number of specific binding sites (Bmax) were determined by Scatchard analysis for the specific binding.
In the experiment studying displacement against specific 3H-NZ-105 (10 nM) receptor binding by other unlabelled compounds, the crude microsomal preparations were pre-incu bated in increasing concentrations of NZ-105, nicardipine and diltiazem for 3 hr. After the incubation, the binding experiments were per formed as stated above. K, values were deter mined from the formula of Cheng and Prusoff (9), K; = IC50/(1 + L/Kd), where L = radioligand concentration and the apparent Hill coefficient of the drug was determined by Hill plot analysis (8) .
45Ca2+ uptake experiments
Experiments were performed essentially as described by Karaki and Weiss (10) . The tho racic aorta was isolated from a male Japanese white rabbit, cut into a spiral strip (3 mm wide and 10 mm long) and placed in an oxygenated physiological salt solution (PSS) of the follow ing composition: 125 mM NaC1, 2.7 mM KCI, 2.0 mM CaC12, 1.2 mM MgC12, 11 mM glucose and 23.8 mM Tris-HCI (pH 7.4), which was bubbled with 100% 02 at 37°C. After the aor tic strips had been equilibrated in PSS for 1 hr under a resting-tension of i g, they were pre treated with NZ-105, nicardipine, diltiazem or the solvent (final concentration, 0.05% etha nol) containing PSS for 1 or 3 hr. Thereafter, the strips were incubated in one of following solutions containing 7.4 KBq/ml of 45CaC12 for 30 min: PSS + solvent, PSS + compound, high-K+ (50 mM) PSS + solvent and high-K+ PSS + compound. After washing with PSS, the arteries were transferred to an isotonic La3+-substituted solution of the following composition: 80.8 mM LaC13, 11 mM glucose and 6 mM Tris-maleate (pH 6.8), ventilated with 100% 02 under ice-cold conditions. Af ter washing in 2 tubes of the La 3 + -substituted solution for 30 min each, the arteries were gently blotted with filter paper, weighed and solubilized in 1 ml of Soluene'R' -350 (Packard) for 3 hr at 50°C. The amount of 45Ca2+ was counted with a liquid scintillation counter us ing a scintillation cocktail (Hionic-fluor'R Packard). The amount of 45Ca2+ uptake was calculated using the following formula:
To determine the washout effects of the compounds, the strips were washed for 1 or 3 hr with PSS at 37°C after incubation with one of the antagonists for 1 hr. Thereafter, the ex periments examining 45Ca2+ uptake were per formed continuously, as described above. 
Statistical analysis
Statistically significant differences were calculated using one-way analysis of variance followed by Turkey's multiple comparison test. 
RESULTS

Association and dissociation kinetics of 3H-NZ 105 and 3H-NTD in DHP receptor binding
The association and dissociation rates of 3H NTD for DHP receptors were rapid (each period up to equilibrium binding and complete dissociation was within 10 min, T1/2 of dis sociation = 2.60 min), as shown in Fig. 1 . The association rate constant (ki) of 3H-NTD was 0.295 min-'nM-', and its dissociation rate constant (k1) was 0.233 min-'. In contrast, 3H -NZ-105 bound more slowly than 3H-NTD; maximum binding was not achieved until more than 2 hr incubation after the 3H-NZ-105 ap plication. The dissociation of 3H-NZ-105 was also significantly slower (T1/2 = 39.88 min) than that of 3H-NTD in the presence of an ex cess concentration of unlabelled nicardipine. The dissociations of both 3H-NZ-105 and 3H NTD were characterized by a significant linear relationship (P < 0.001, r = 0.993 and P < 0.01, r = 0.994 for 3H-NZ-105 and 3H-NTD, respectively) between the logarithm of residual binding and the elapsed time. The k1 of 3H NZ-105 was 0.0042 min-'nM-1, and its k-1 was 0.019 min'.
The DHP receptor density and each 3H-com pound affinity Specific 3H-NZ-105 and 3H-NTD bindings were approximately saturable for DHP recep tors on rabbit aortic microsomes (Fig. 2) (Fig. 3, Table 2 ). These results indicate that the receptors specific for 3H-NZ-105 were the same as those for both unlabelled NZ-105 and nicardipine. Therefore, we identified the specific binding sites of 3H-NZ-105 with DHP receptors. The affinity of NZ-105 for DHP re ceptors was 8.9-fold less potent than that of nicardipine. The slope factor obtained by pseudo Hill analysis was close to 1 ( Table 2) . In contrast, a benzothiazepine derivative, dil tiazem, enhanced 3H-NZ-105 specific binding, with the enhancement reaching about 160% at a 100 ,u M diltiazem concentration (Fig. 3) .
Effects of NZ-105 and other calcium antago nists on transmembrane 45Ca2+ uptake NZ-105, nicardipine and diltiazem at 1,uM had no effects on the basal level of transmem brane 45Ca2+ uptake in polarized rabbit aortic strips (Table 3) .
In a high-K+ (50 mM) bathing solution, the transmembrane 45Ca2+ uptake was significant ly increased (153.6 ± 23.5,umoles/kg, P < 0.01, n = 8) in comparison with that in the polarized arteries (45.9 ± 5.7 p moles/kg, n = 8). NZ-105, nicardipine and diltiazem con centration-dependently inhibited the increment in transmembrane 45Ca2+ uptake following ex posure to a high-K+ bathing solution (Fig. 4) . The order of the inhibitory potency for 1 hr incubation with each compound (0.1 M M) was nicardipine (100%) > NZ-105 (67%) > dil tiazem (49%). The inhibitory efficacy of NZ-105 (1 ,uM) was about the same as that of nicardipine (0.01 uM) for 1-hr incubation, and that of NZ-105 (0.1 uM) was about the same as that of diltiazem (1 ,uM) (Fig. 4A) . These results indicate that the effect of NZ-105 was about 100 times less potent than that of nicardipine and was about 10 times more potent than that of diltiazem for 1-hr incubation. The inhibi tory efficacy of NZ-105 at all concentrations became larger as the incubation time was in creased (Fig. 4B) . However, we were not able to calculate the ratio between the inhibitory efficacy of NZ-105 and nicardipine for 3-hr incubation, because the inhibitory efficacy of nicardipine at all concentrations had reached a basal 45Ca2+ uptake level by 3 hr of incuba tion. Figure 5 shows the recovery effects pro duced by washout of the arteries with PSS. The inhibitory efficacy of NZ-105 (0.1 and 1 ,uM) against the high-K+-induced transmem brane 45Ca2+ uptake increment did not change with increasing duration of the washout period. That of nicardipine (0.01 ,uM) partially recovered with washout for either 1 or 3 hr (significant difference between before washout and after washout). That of diltiazem (1 uM) completely recovered even with washout for only 1 hr. Fig. 5 . Recovery effects after washout of NZ-105, nicardipine and diltiazem from tissues on 45Ca2+ uptake at 37"C into depolarized (high-K+ (50 mM) conditions) rabbit aortae. Washout effects on 45Ca2+ uptake without the washout of each compound (A), and after washout for 1 hr (B) and for 3 hr (C). Results are the mean ± S.E.M. of four determinations. The change is significant at ##P < 0.01, as compared to the vehicle control (results obtained in the absence of compounds); *P < 0.05 and **P < 0.01, versus high-K+ (50 mM) control (results obtained in the absence of compounds).
DISCUSSION
We previously demonstrated that NZ-105 has a characteristic vasodilatory effect attribut able to its calcium antagonistic effect in iso lated rabbit vascular tissues (3) . In the present investigation on the mechanisms underlying this vasodilatory response, NZ-105 and other calcium antagonists concentration -dependently inhibited a high-K+ (50 mM)-induced trans membrane 45Ca2+ uptake increment, possibly through the VDCs of the arteries. However, the incubation time with 45CaC12 solution was so long (30 min) that we cannot ignore the in fluence of 45Ca2+ efflux in this experiment. We consider the present data to be accept able, because all the experiments were per formed under the same conditions. We consid er these results to be in agreement with other earlier electrophysiological observations (11): NZ-105 also blocked the whole-cell calcium current in vascular smooth muscle cells in a dose-dependent manner. The results of Tamura et al. as well as those of the present study confirm that NZ-105 is a VDC antago nist. On the other hand, NZ-105, nicardipine and diltiazem did not affect 45Ca2+ uptake content in polarized arteries, and this result suggests the two following ideas: NZ-105 and other calcium antagonists may not affect basal calcium uptake through the VDCs under pola rized conditions or the effect may reflect other mechanisms of maintaining basal calcium up take content, which can not be blocked by general calcium antagonists including NZ-105, e.g., receptor-operated calcium channels and/or sodium-calcium exchanges.
The present receptor binding studies indi cate that NZ-105 binds the same receptors that are bound by all other 1,4-DHP deriva tives (6, (12) (13) (14) (15) , that the binding is of a single class and that positive or negative cooperative interactions are absent. On the other hand, diltiazem enhanced the specific 3H-NZ-105 binding, which may reflect a positive allosteric interaction between benzothiazepine receptors and NZ-105 binding DHP receptors, which is in agreement with earlier observations (16, 17) .
One of the most significant findings of the present study is that the association rate of NZ-105 for DHP receptors and the time course effect of NZ-105 on transmembrane calcium mobilization through the VDCs corre late closely. The formation of the 3H-NZ-105 and DHP receptor protein complex was very much slower than that of 3H-NTD complex formation. Moreover, the affinity of 3H-NZ 105 for DHP receptors, which appeared as the Kd value, was lower than that of 3H-NTD without changing the Bmax value in the satura tion assay, and the affinity of unlabelled NZ 105 was also less potent than that of nicardi pine in the competition assay. The ratio of the potencies between NZ-105 and nicardipine, in the present binding study, was about equal to the previously reported ratio (3). In addition, we confirmed that both 3H and unlabelled NZ-105 yielded roughly the same dissociation constant (about 4 to 5 nM) in different assay systems: a saturation assay and a competition assay. As the Bmax values of each compound were about the same, the potencies of the physiological effects may be controlled by their binding affinities and association rates for DHP receptors. By producing identical physiological reactions from both compounds, our present results indicate that we may need a 6 to 9-fold higher concentration of NZ-105, in comparison with NTD and nicardipine, or that NZ-105 may require a longer incubation period than either NTD or nicardipine. The present data further support the results of our previous receptor study using 3H-NTD and our previous results from in vitro studies (3) . The difference in binding potencies between NZ-105 and nicardipine may be diminished by increasing the incubation time. Therefore, if we increased the duration of the incubation time for binding of NZ-105 to DHP receptors, we would presumably be able to obtain a much smaller difference in the binding poten cies of NZ-105 and nicardipine. However, longer incubations than those employed in the present study were not possible under these conditions (25°C), because the microsomal preparation might deteriorate during a longer incubation, which would change the character istics of the preparation. On the other hand, the effect of NZ-105 on transmembrane 45Ca2+ uptake under high -K+ conditions was less potent than that of nicardipine with a 1-hr incubation period. The inhibitory efficacy of NZ-105 on the 45Ca2+ uptake became larger as the incubation period with NZ-105 in creased. This response to increasing the dura tion of NZ-105 incubation may also depend on its rate of association to DHP receptors. In terms of 45Ca24 uptake, however, the ratio of potencies between NZ-105 and other calcium antagonists could not be compared with the above-mentioned ratio of receptor binding potencies, because the experimental conditions differed in these two studies, i.e., there were variations in the precise incubation times with the experimental compounds and/or differ ences between intact tissue and membrane preparations. Another important finding is that the dis sociation rate of NZ-105 from DHP receptors was also connected with the time-course effect of NZ-105 on transmembrane calcium uptake through the VDCs after washout. The com plex of 3H-NZ-105 and DHP receptor proteins was also very resistant to dissociation by an excess concentration of an unlabelled DHP. The dissociations of both 3H-NZ-105 and 3H NTD could be attributable to a single phase kinetic pattern between drugs and DHP recep tor sites, because the dissociation kinetics were characterized by a significant linear re lationship between the logarithm of residual binding and the elapsed time. On the other hand, NZ-105 and nicardipine but not dil tiazem maintained significant inhibition of 45Ca2+ uptake in spite of the absence of drug from the bathing solution after washout for either I or 3 hr. NZ-105 (1 uM) barely reco vered its inhibitory efficacy after washout not only for 1 hr but also for 3 hr, and nicardipine (0.01 u M) partly recovered its efficacy after only 1 hr of washout. However, nicardipine (0.01 u M) maintained about the same inhibi tion of transmembrane 45Ca2+ uptake in spite of an increasing washout period, in agreement with our previous observations (3). These re sults indicate that both compounds remained bound to DHP receptors on the cell surface even after washout, but NZ-105 is more diffi cult to dissociate from DHP receptors on VDCs. The transmembrane 45Ca2+ uptake re sults are consistent with the results of the pres ent receptor binding study.
We speculate that the slow onsets of the vasodilatory and calcium antagonistic effects of NZ-105 can be explained only by the asso ciation rate for specific receptors, but the ex planation of its long-lasting property is attri butable not only to the dissociation rate from specific receptors but also to that from non specific binding sites such as the membrane phospholipid bilayer. In the last few years, some 1,4-DHP calcium antagonists having slow onset of and recovery from certain phys iological effects in in vitro have been demon strated (18) (19) (20) . In clarifying the mechanisms of the especially long-lasting effects of these compounds, some reseachers have investigated both the properties of dissociation kinetics from DHP receptors and those from non-spe cific sites such as the membrane phospholipid bilayer (18, 21) . The binding ratio of 3H-NZ 105 to non-specific sites against total binding content was much larger than that of 3H-NTD (data not shown). The large ratio of non-spe cific binding sites of 3H-NZ-105 was main tained after the dissociation from specific binding sites (DHP receptors) by an excess concentration of unlabelled nicardipine (data not shown). Karasawa and Kubo reported pre viously that the efflux rate of 3H-KW-3049 from strips of canine coronary arteries was less than that of 3H-NTD (18) . They proposed that this property of KW-3049 could clearly explain the pharmacological observation that the in hibitory effects of KW-3049 on depolarization induced contractions continued even after re peated washout from the tissues. On the other hand, it has been reported that over 94% of amlodipine molecules existed in an ionized form in extracellular solution buffered to pH 7.4 (22) , and that the long-lasting vasodilatory effect of amlodipine as a charged 1,4-DHP in in vitro experiments can be explained as a slow dissociation from the binding sites that are not only DHP receptors (specific binding sites) but also in the membrane phospholipid bilayer (non-specific binding sites) (21, 22) . In the case of NZ-105, the slow recovery from vasodilatory and calcium antagonistic effects in vitro might be explained by these hypotheses. However, it is difficult to explain the more de tailed mechanism of binding to non-specific sites in the membrane phospholipid bilayer, as the formation of NZ-105 in a bathing solution buffered to pH 7.4, as in general physiological conditions, is not clear.
In conclusion, NZ-105 is an antagonist of VDCs, and this antagonism is due to binding of DHP receptors on VDCs. Moreover, the very slow onset of and recovery from vasodila tion and the calcium antagonistic effects of NZ-105 may be explained by the slow and long-lasting inhibition of transmembrane cal cium uptake, which accompanies extremely slow association with DHP receptors and very slow dissociation from them in the VDC sys tem.
